POLA1 and mantle cell lymphoma: Based on the aforementioned data, Pola is also under exploration in patients with R/R MCL in an ongoing phase II trial (NCT04659044) that is recruiting patients receiving the same combination therapy of Pola, venetoclax, and rituximab.